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A B S T R A C T
Alzheimer’s disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ)
peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways.
The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion
(sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding
pharmacological approaches that may act via diﬀerent signaling cascades and thus stimulate non-amyloidogenic
cleavage through ADAM10. This review emphasizes the eﬀects of natural compounds on ADAM10 modulation,
which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New
treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the
wide variety of ADAM10 substrates.
1. Introduction
The amyloid-β precursor protein (AβPP) is a transmembrane protein
found in mostly all cell types. In pathological conditions, as Alzheimer’s
disease (AD), AβPP is mainly processed by β- and γ-secretases, resulting
in the production of amyloid-β (Aβ) peptides, the main players for the
generation of senile plaques [1]. In physiological conditions, AβPP is
mainly cleaved in the middle of the Aβ region by an α-secretase,
identiﬁed as A Disintegrin And Metalloproteinase 10 (ADAM10), re-
leasing a soluble fragment (sAβPPα) in a non-amyloidogenic and neu-
roprotective pathway [2]. Therefore, reduction of Aβ formation and
sAβPPα production by stimulating the non-amyloidogenic pathway
seem promising strategies for the AD treatment [3]. In addition, the
non-amyloidogenic cleavage of AβPP remains largely unknown, mainly
regarding pharmacological approaches that may aﬀect diﬀerent
signaling pathways and improve the ADAM10 activity. This biblio-
graphical review analyzes articles published in diﬀerent levels of sci-
entiﬁc evidence. Studies from Medline/PubMed databases (1990–2018)
were included. These databases were chosen due to the great number of
scientiﬁc articles with international availability focused on health
follow-up, besides being provided with the most qualiﬁed forms of
online search. For this, the search descriptors were deﬁned according to
the Medical Subject Headings (Mesh), using the vocabulary structured
with the terms "ADAM10 protein", "Alzheimer disease", "alpha secre-
tase" and "natural products". According to this speciﬁc search, about 70
studies were found within this theme, of which compounds of plant or
animal origin were included for analysis.
This review emphasizes natural compounds that can directly or
indirectly stimulate the neuroprotective mechanism achieved by
ADAM10 induction, besides highlighting the challenges of this protein
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as a biomarker for AD therapy.
2. ADAM10 and Alzheimer’s disease
ADAM10 belongs to the ADAMs family of proteins, which comprises
transmembrane, as well as secreted metalloproteinases with functions
in cell adhesion and proteolytic processing of diverse cell surface re-
ceptors ectodomains and signaling molecules [4]. ADAM10 substrates
comprise more than 40 molecules, including adhesion molecules (e.g.,
cadherins), chemokines (e.g., CX3CL1), growth factors (e.g., EGF and
Tumor Necrosis Factor - α), signaling receptors, ligands (e.g., Notch
receptor and Fas ligand) and AβPP [5–7].
ADAM10 is a multimodular transmembrane protein constitutively
expressed in neurons, vascular cells, leukocytes and tumor cells [8]. It is
synthesized in the endoplasmic reticulum (ER) as an inactive zymogen
containing C-terminal, transmembrane, cysteine-rich, disintegrin and
zinc-binding metalloprotease domains. There is also a pro-domain,
which maintains the protease in a latent inactive form, via a cysteine
switch mechanism, where a cysteine residue in the pro-domain co-
ordinates the zinc ion in the catalytic site, preventing proteolytic ac-
tivity [9]. During transport to the plasma membrane, ADAM10 is N-
glycosylated at four positions and undergoes maturation through pro-
domain removal by proprotein convertases [10]. Pro-ADAM10 has a
molecular weight of ∼90kDa and after pro-domain removal, the full-
length active ADAM10 has ∼65kDa [10,11].
Ectodomain shedding of ADAM10 leaves a ∼10kDa membrane-
anchored C-terminal fragment and releases a ∼55kDa soluble
ADAM10. Therefore, apart from its role in protein shedding and the
initiation of regulated intramembrane proteolysis of several substrates,
ADAM10 itself is subject to a similar proteolytic cascade by other
ADAMs, such as ADAM9 and 15 and by γ-secretase. The γ-secretase
presenilin releases ADAM10 intracellular domain, which then translo-
cates to the nucleus and localizes to nuclear speckles, thought to be
involved in gene regulation. This suggests that ADAM10, in addition to
its important function as a membrane-tethered sheddase, also has the
potential to be a signal transducing protein [12].
ADAM10 can be diﬀerentially regulated from transcriptional to
translational and post-translational levels [7,13]. In neuronal cells,
ADAM10 is localized at the synapses, at the presynaptic vesicles and at
the postsynaptic side [14,15]. ADAM10 shedding activity at the synapse
is under the control of traﬃcking mechanisms. SAP97 mediates
ADAM10 traﬃcking from dendritic Golgi outposts to the synapse upon
protein kinase C (PKC) activation [14,16], while AP2 interaction
triggers ADAM10 endocytosis [17]. Notably, ADAM10 is a relevant
enzyme in the synapses because its activity participates in the re-
modeling of the spines [18]. Indeed, its activity is ﬁnely regulated by
activity-dependent synaptic plasticity [17].
The results of ADAM10 regulation, as well as its action as a shedding
molecule, are related to diﬀerent physiological and pathological con-
ditions, such as cancer and AD. For instance, the synaptic levels of
ADAM10 are signiﬁcantly reduced in AD patients hippocampi com-
pared to age-matched healthy control subjects [19]. Since the seminal
paper from Lammich and co-workers (1999), demonstrating that
ADAM10 has α-secretase activity and is responsible for the proteolytic
processing of AβPP within the Aβ stretch, this metalloproteinase has
been increasingly studied [20]. The argument that captivates and at-
tracts interest from researchers is the strategy of increasing its activity
in order to decrease Aβ production and hence, preventing or avoiding
AD appearance or progression.
AβPP is a type I transmembrane glycoprotein constitutively ex-
pressed in many types of mammalian cells, including neurons. It serves
as the precursor of Aβ, whose sequence includes 28 amino acids of the
extracellular and 12–15 residues of the membrane-spanning region of
AβPP. The sequential AβPP cleavage by β and γ secretases is the basis of
the amyloid cascade hypothesis, ﬁrst proposed by Hardy and Higgins in
1992 [21]. Although it has been criticized over the years alternatively
raised hypothesis were not able to fully explain the disease mechan-
isms.
According to the amyloid hypothesis, AβPP ectodomain is detached
from the neuronal membrane through sequential proteolytic cleavages
that involve α, β and γ-secretases [22]. The main β-secretase involved
in AβPP cleavage at β-site is the cleaving enzyme β-secretase (BACE-1)
[23]. The action of α-secretases, instead of β-, drives the pathway to a
non-amyloidogenic cleavage, avoiding Aβ production. In the non-
amyloidogenic pathway, AβPP is cleaved mainly by ADAM10, between
Lys-16 and Leu-17 in the middle of the Aβ region, thus, releasing
sAβPPα - a structure with neurotrophic and neuroprotective functions,
retaining a 83-amino acid membrane-bound fraction (α-CTF or C83)
residue in the membrane. The subsequent cleavage of α-CTF by γ -se-
cretases liberates P3, which is supposedly beneﬁcial and not found in
amyloid plaques [24] (Fig. 1).
Easily available, low invasive, cost-eﬀective and early-stage disease
detection biomarkers are urgently needed in AD clinical practice.
Perhaps the massive failure faced so far in clinical trials for AD is due to
the fact that the drugs were tested in patients with established dementia
and a few in patients with mild cognitive impairment (MCI), but not
Fig. 1. Non-amyloidogenic and amyloidogenic pathways in AD through consecutive cleavages of AβPP protein in the membrane by ADAM10 and BACE-1, re-
spectively.
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early in the disease process - in prodromal or preclinical stages.
Peripheral blood is a good source to investigate AD biomarkers, despite
all diﬃculties regarding assay standardizations and replicability of re-
sults [25]. Among the peripheral tissues, platelets present the highest
AβPP expression levels [26]. They store and liberate neurotransmitters
and carry appropriate transporters and receptors, normally expressed
by neuronal cells [27]. In addition, platelets can produce all AβPP
fragments found in neurons, thus indicating that they have α, β and γ-
secretases activities and that, as well as neurons, can process AβPP
through the amyloidogenic and the non-amyloidogenic pathway.
Finding the same products from the secretases in platelets and in neu-
rons, it is acknowledged that the formers are easily accessible and po-
tentially useful as a clinical tool to monitor the eﬀects of new therapies
based on β and γ-secretases inhibition and/or α-secretases activation
[28]. In healthy individuals, the cleavage by α-secretase seems to be the
dominant way used by platelets since the detected levels of sAβPPα are
much higher than the levels of sAβPPβ [28].
Two studies have demonstrated that ADAM10 is the primordial α-
secretase in neurons, which are the most aﬀected cells in AD [29,30]. In
addition, its beneﬁcial role in alleviating the Aβ burden in AD has been
demonstrated both in vivo and in vitro [31,32]. Furthermore, in addition
to the four established AD susceptibility genes, AβPP, Presenilin-1,
Presenilin-2 [33] and Apolipoprotein E [34], increasing evidence in-
dicates that ADAM10 is a candidate for AD susceptibility gene [35,36].
As a consequence of the several roles of ADAM10 in the brain, it not
only would act as a major α-secretase, but also can aﬀect tau pathology,
synaptic functions, hippocampal neurogenesis, and gliogenesis by in-
teracting with its substrates [2].
3. ADAM10 modulation by natural compounds
Based on the Aβ hypothesis, compounds that lower Aβ peptide brain
levels, either by inhibiting its production or increasing its clearance and
those that prevent Aβ aggregation represent disease-modifying ther-
apeutic agents, which should alter its course. If we assume that the
amyloidogenic hypothesis is important, one of the therapeutic strate-
gies for AD prevention will be the inhibition of Aβ42 formation, mis-
folding and aggregation until substantial neurodegeneration is devel-
oped and the cognitive decline appears as the main symptom of this
progressing disease [37–39] .
The non-amyloidogenic pathway and the speciﬁc role of ADAM10 in
AD neuropathology have been described above. The administration of
drugs directed to increase ADAM10 activity is an interesting and future
therapeutic option for AD treatment. The main feature of the α-secre-
tase activation pathway is the increase in the generation of sAβPPα,
which has neurotrophic, neuroprotective properties and is involved in
the maintenance of dendritic integrity in the hippocampus. Hick and
colleagues reported that acute application of exogenous recombinant
sAβPPα to mouse models of AD improves synaptic strength and en-
hance memory performance, while sAβPPβ was ineﬀective [40]. In
addition, the α7-nAChRs has been recently identiﬁed as a crucial
physiological receptor speciﬁc for sAβPPα, but not for sAβPPβ [41].
Therefore, this preclinical data reinforce the hypothesis that en-
hancing brain sAβPPα levels is a potential strategy to improve AD-re-
lated symptoms and attenuate synaptic deﬁcits. It has been demon-
strated that a virus-mediated intracranial expression of sAβPPα can
mitigate the Aβ-related synaptic deﬁcits of APP/PS1 mice in vivo [42].
sAβPPα has synaptotrophic eﬀects in an Aβ-independent pathology
[41].The functional synaptic plasticity was also modulated by sAβPPα
in the hippocampus, including long-term potentiation (LTP) and long-
term depression (LTD) of synaptic transmission, through the activation
of the N-methyl-D-aspartate subtype of glutamate receptors (NMDAR)
[40]. Furthermore, the beneﬁcial eﬀects of sAβPPα could be explained
by the inhibition of BACE-1 activity. Peters-Libeu and colleagues re-
ported that sAβPPα can directly inhibit BACE-1, suggesting that it could
be an endogenous ligand of this enzyme [43]. In addition, Tan and
colleagues reported that direct administration of sAβPPα into the hip-
pocampus has a potential therapeutic impact by increasing the process
of neurogenesis [44]. Therefore, the stimulation of the non-amyloido-
genic pathway could signiﬁcantly reduce Aβ release and sAβPPβ levels,
being a suitable therapeutic strategy in AD. Furthermore, both en-
zymes, ADAM10 and BACE-1 compete for the AβPP cleavage, therefore
potentiating ADAM10 activity might inhibit the neurotoxic amyloid
generation. Moreover, sAβPPα can prevent the activation of the JNK
stress kinase-signaling pathway and has an anti-apoptotic eﬀect [45].
Therefore, a drug able to promote ADAM10 activity in the brain can
provide a multi-target therapy for AD to reduce Aβ generation and limit
its toxic synaptic signaling, increasing Aβ clearance and favoring neu-
rogenesis.
In this framework, in order to increase therapy eﬀectiveness and to
reduce the occurrence of potential side eﬀects, the challenge is directly
targeting the drug to the brain, attempting to tackle a brain and disease-
speciﬁc mechanism able to regulate ADAM10 activity. Undesirable ef-
fects obtained by non-speciﬁc ADAM10-targeting might be found in
cancer proliferation [46], cell adhesion [47–49], promotion of T cell/
NK-cell precursor [50], inﬂammation [51,52] and others, since several
in vitro studies have shown a wide variety of ADAM10 substrates [53].
A potential strategy could be the use of natural compounds for ther-
apeutic approaches to treat AD, as in the recent years they have been
shown to increase ADAM10 expression. Therefore, it seems more ap-
propriate to promote the long-term intake of natural origin products
that are being used for a long time in indigenous cultures, and mainly
through the consumption of such compounds by diet. In this context, it
recently emerged that some natural compounds such as the plant ex-
tracts Ginkgo biloba and green tea–epigallocatechin-3-gallate can spe-
ciﬁcally activate the α-secretase cleavage of AβPP, as will be shown
below (Fig. 2).
In AD, ADAM10 activators could be disease-modifying therapies
since they could increase the cognitive process and lead to slow neu-
ronal loss and functional memory decline. Moreover, disease-modifying
therapies should be introduced early in the course of a disease to
achieve maximum beneﬁt for patients. In addition to AD, ADAM10 is a
suitable therapeutic target for other cognitive loss diseases such as
Fragile X Syndrome (FXS) and autism spectrum disorder [54,55]. Fur-
ther research is required to understand the molecular mechanisms of
these agents involved in ADAM10 activation and their beneﬁcial and
adverse eﬀects in patients with AD and other diseases.
3.1. Natural α-secretase inducers as potential disease modiﬁers
Three of membrane-anchored zinc-dependent metalloproteinases,
ADAM10, ADAM17 and ADAM9 display alpha-secretase activity
[56,57]. However, since the individual knock-out of these proteinases
in neither case completely prevented alpha-secretase processing of
AβPP, it is likely that diﬀerent ADAMs are compensating mutually, and
under diﬀerent conditions may contribute to alpha-secretase cleavage
of AβPP.
3.1.1. Retinoids
Several biological processes are regulated by Vitamin A (all-trans-
retinol), like embryonic development, growth, diﬀerentiation and cel-
lular apoptosis, as well as brain functions [58]. Derivate from pro-vi-
tamin A carotenoids, these can be obtained from colorful fruits and
vegetables or from animal sources such as dairy, liver and egg yolk [59]
which are converted into retinal and subsequently to retinoids [60].
Retinoids play important roles in the regulation of adult brain functions
such as neuronal diﬀerentiation, neurite growth, neurotransmitter re-
lease and LTP [61].
Currently, the etiology of late-onset AD remains unclear, however,
previous studies reported that retinoic acid (RA) signaling is essential
for normal brain maintenance [62]. Retinoid signaling is mediated by
two classes of receptors, namely, retinoic acid receptors (RARα, β, and
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γ) and retinoid X receptors (RXRα, β, and γ). Both receptor types are
widely distributed in the brain, being RARα and RXRα the main sub-
types of receptors found in the hippocampus playing an important role
in neuronal plasticity. Furthermore, Chiang and colleagues described
that RARβ is also essential in hippocampal CA1 LTP, spatial learning
and memory [63].
The research study of Corcoran and colleagues was the ﬁrst de-
monstrating that a loss of brain retinoid acid function leads to Aβ de-
position in the brain of adult rats [64]. They suggest the decrease of
cholinergic function and in acetylcholinesterase expression due to a
lack of RA before Aβ deposition. In a preclinical study, Tippmann and
colleagues evaluated the eﬀects of acitretin, a synthetic retinoid eﬀec-
tive for the treatment of psoriasis. This drug stimulated ADAM10 pro-
moter activity increasing mature ADAM10 as well as α-secretase ac-
tivity. The authors suggested that acitretin activates the RAR/RXR-
heterodimers bound to the ADAM10 promoter, through the major vi-
tamin A metabolite all-trans retinoic acid, and thereby upregulates
ADAM10 transcription [65]. Furthermore, acitretin regulates some
genes linked to the AD neuropathology, such as choline acetyl-
transferase (ChAT) [66].
In the preclinical Tg2576 mouse AD model, Jarvis and colleagues
reported that the administration of RARα agonist signiﬁcantly de-
creased brain Aβ production and that these eﬀects were receptor spe-
ciﬁc because neither RARβ nor γ-agonists aﬀected Aβ production [67].
Moreover, in neuronal cortical cultures, RARα agonists were demon-
strated to be neuroprotective, as they prevented Aβ-induced neuronal
cell death. Therefore, RARα agonists induce ADAM10 expression and
have multiple eﬀects apart of AβPP processing. In the non-amyloido-
genic pathway, they decrease intracellular Aβ production and are
neuroprotective, indicating that RARα agonists have therapeutic po-
tential for the treatment of late-onset AD [67].
Using the same AD preclinical model, Gonçalves and coworkers
evaluated the eﬃcacy of several retinoid receptor agonists including
AM 580, CD2019 and CD437, which are selective RARα, RARβ and
RARγ agonists, respectively. They speciﬁcally demonstrated that acti-
vation of RARα receptor signaling pathway favors Aβ clearance by
upregulating the enzymes NEP and IDE and modulating the release of
proinﬂammatory cytokine TNF-α by glial cells [68].
Likewise, in patients with mild to moderate AD, a key study per-
formed by Endres and coworkers demonstrated that acitretin treatment
signiﬁcantly increased CSF sAβPPα levels. Therefore, this research
conﬁrms preclinical data and was the ﬁrst human evidence of an in-
crease in ADAM10 activity by this drug in AD patients. In addition, this
study gives support to the potential use of retinoid agonists as potential
disease-modifying therapy drugs for AD treatment [69].
Similarly, Fukasawa and co-workers observed that Tamibarotene, a
retinoid receptor agonist, lowered the insoluble Aβ40 and Aβ42 levels in
AβPP23 transgenic mice by upregulating α-secretase expression [70].
Furthermore, in association with HX630, an RXR agonist, Tamibarotene
signiﬁcantly enhanced the cognitive process in the preclinical mouse
model as observed by the Morris water maze test [71]. In addition,
Tamibarotene has been also administered to 13-month-old SAMP8 mice
and improved memory/learning. Likewise, this cognitive improvement
could be due to RA activation and increased hippocampal ADAM10
mRNA expression and protein production, leading to the release of the
soluble neuroprotective fragment sAβPPα [72].
In APP/PS1 transgenic mice, Ding and colleagues administrated all-
trans retinoic acid (atRA) 20mg/kg, intraperitoneally for 8 weeks [73].
This treatment improved spatial learning and memory compared with
the vehicle-treated animals, assessed by the Morris water maze test.
Furthermore, atRA inhibited Aβ formation, tau hyperphosphorylation,
glial activation, and prevented loss of presynaptic terminals. Authors
suggest that neuroprotective eﬀects of atRA in AD could be also asso-
ciated with an increase in the ChAT levels. However, potential adverse
side eﬀects of higher atRA concentrations could restrict its potential
clinical applications in AD therapeutics.
Bexarotene is a highly speciﬁc RXR receptor agonist, which has a
suitable safety proﬁle in humans. In a clinical trial study, Cummings
and colleagues (registered in ClinicalTrials.gov under the identiﬁer
NCT01782742) conducted a double-blind, randomized, placebo-con-
trolled, parallel group study of a single dose (300mg/day) of bexar-
otene. This study also included groups of AD patients, carriers and non-
carriers of APOE allele. Patients were treated for 4 weeks and an im-
provement was observed in the APOE non-carriers treated group,
showing a signiﬁcant reduction in brain Aβ levels compared with the
APOE4 carrier group [74].
In a recent clinical research, Ghosal and coworkers evaluated the
eﬀects of Bexarotene on the alteration of Aβ metabolism in cognitively
healthy individuals (NCT02061878) and reported a problem with
Bexarotene due to its poor CNS penetration in cognitively healthy
Fig. 2. Natural compounds can stimulate ADAM10 maturation and/or activation. The increased activity of ADAM10 in the membrane promotes the greater release of
sAβPPα, a neuroprotective cleavage product of AβPP.
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subjects [75].
It is important to emphasize that studies using natural products as a
source of retinoids are needed and were not found in this literature
search, so that only assays induced by retinoic acid, modulation of their
receptors or of synthetic origin were analyzed.
3.1.2. (-)-Epigallocatechin-3-Gallate
(-)-Epigallocatechin-3-gallate (EGCG) is the major polyphenol of the
Camellia sinensis leaf, from which green tea is produced. EGCG has
antioxidant properties that might be useful since oxidative stress bears
signiﬁcance in AD development. It has been reported that this natural
polyphenol shows neuroprotective properties in hippocampal neurons
and neuronal-like cultures, inhibiting Aβ oligomer toxicity [76–78].
Apart of its potential antioxidant activity, neuroprotective EGCG
properties could be explained through the modulation of several sig-
naling pathways, among them the protein kinase C (PKC)/α-secretase/
sAβPPα pathway, leading to increasing the α-secretase activity.
A report by Obregon and coworkers was the ﬁrst research sug-
gesting that EGCG was able to induce ADAM10 maturation and in ad-
dition to favoring AβPP non-amyloidogenic α-secretase processing in
neuronal cells. They also describe the molecular mechanism involved in
EGCG modulation of ADAM10 activity through estrogen receptor
[79,80]. Additionally, preclinical research studies conﬁrm that EGCG
induced non-amyloidogenic sAβPPα release and inhibited the genera-
tion of Aβ peptide via a PKC-dependent α-secretase activation. In AD
preclinical models, such as APP/PS1 mice, the administration of EGCG
induced cognitive improvement associated with the activation of brain
insulin receptor [81]. In addition, there was Akt activation and in-
hibition of GSK3β signaling with a signiﬁcant decrease in the hippo-
campal Aβ42 levels, and an inhibition of JNK/TNFα pathway (anti-in-
ﬂammatory). In the SAMP8 mice model of AD and aging, EGCG
signiﬁcantly prevented Aβ42 accumulation through the overexpression
of NEP [82]. Likewise, in the same mouse model, Guo and coworkers
reported that EGCG improved memory function evaluated by the Morris
water maze through the decrease of Aβ42 and BACE-1 levels. Likewise,
the administration of EGCG (3mg/kg for 1 week) in a mouse model of
AD was able to prevent Aβ42-induced memory loss. The improvement in
memory function was related to a decrease of Aβ42 levels and a de-
crease in β-secretase levels [83].
Furthermore, additional targets involved in EGCG neuroprotection
have been suggested, such as modulation of tyrosine-phosphorylation-
regulated kinase 1 A (DYRK1 A) that could be important in Down’s
syndrome neuropathology. Recent studies give support to the use of
EGCG as a cognitive enhancer in Down’s syndrome patients. Torre and
coworkers (NCT01699711) reported that patients with Down’s syn-
drome treated with EGCG (9mg/kg per day) during 12 months in
parallel with cognitive training presented beneﬁcial eﬀects on memory
compared to placebo-treated patients or the placebo plus cognitive
training group in cognitive tests [84]. Despite the fact that this clinical
trial has so far only been performed in Down’s syndrome patients
evaluating the eﬀects of EGCG on DYRK1 A and AβPP and its role im-
proving cognitive performance, its action in AD should also be con-
sidered.
In addition, a clinical trial completed in 2015 (NCT00951834)
studied the eﬀect of an EGCG formulation called Sunphenon in early-
stage AD cases, however, the results about the potential disease-mod-
ifying eﬀects of the drug were not yet reported.
3.1.3. Cryptotanshinone
The dried root of Salvia miltiorrhiza BUNGE (Labiatae), called
‘Danshen’ in China, is a very popular traditional Chinese medicine.
Preclinical studies have shown that this plant possesses multiple phar-
macological activities and has been used for the treatment of various
diseases such as cardiovascular, blood circulation disorders, angina
pectoris, hyperlipidemia, insomnia, and inﬂammation [85]. Analysis of
the chemical constituents of S. miltiorrhiza root revealed the presence of
two classes of secondary metabolites. Among them, a family of lipid-
soluble, hydrophobic diterpene pigments known as tanshinones and
water-soluble, hydrophilic, polyphenolic compounds mainly consisting
of caﬀeic acid monomers, dimers, trimers or tetramers in the form of
salvianolic acids.
Preclinical evidence suggests that cryptotanshinone has neuropro-
tective eﬀects and provides potential therapeutic beneﬁt against neu-
rodegenerative disorders such as AD. Interestingly, tanshinone deriva-
tives cryptotanshinone and 15, 16-dihydrotanshinone I improve
cognitive function and learning in scopolamine-treated rats through the
inhibition of acetylcholinesterase activity in a dose-dependent manner
[86]. Likewise, it was reported that cryptotanshinone shows anti-
apoptotic eﬀects in rat cortical cultures against glutamate-induced
apoptosis through Bcl-2 activation, which is a downstream signaling
target of PI3K/Akt pathway and mediated the neuroprotective eﬀect
[87]. In addition, the activation of this PI3K pathway in cortical neu-
rons enhances α-secretase activity [88]. Cryptotanshinone prevents
Aβ42-induced apoptosis and cytotoxicity in SH-SY5Y [89]. Moreover, in
N2a mouse neuroblastoma cells it reduced Aβ production and fa-
cilitated activation and translocation of ADAM10 and PKC-α to the cell
membrane [90]. The increase of ADAM10 activity and secretion of
sAβPPα could be attributed to a mechanism involving PKC activation.
In the APP/PS1AD transgenic mouse model 4 months of daily oral
cryptotanshinone administration beginning at 3 months of age, sig-
niﬁcantly improved learning and spatial navigation with a reduction of
amyloid plaque deposition. Due to the ability to cross BBB, its periph-
eral administration was able to stimulate ADAM10-mediated AβPP
cleavage, increase sAβPPα production, and reduce the amounts of Aβ42
peptides in CNS [91].
3.1.4. Ligustilide
Ligustilide is a natural lipophilic compound present in the
Umbelliferae family of medicinal plants. Some preclinical studies sug-
gest that this natural compound might be a promising therapeutic
candidate for the treatment of age-related neurodegenerative diseases,
such as AD. A recent preclinical study in APP/PS1 mice demonstrated
that intragastrically administered ligustilide (30mg/kg) for 14 weeks,
starting at 8.5 months of age, signiﬁcantly improved the neurobeha-
vioral deﬁcits of transgenic compared with control wild-type mice.
Authors suggested that ligustilide-evoked cognitive eﬀects were medi-
ated by an increase in non-amyloidogenic pathway, speciﬁcally by in-
creasing ADAM10 expression and enzymatic activity [92]. Logically,
this eﬀect on ADAM10 decreased soluble and insoluble Aβ42 levels and
plaque deposition in the brains of APP/PS1 mice.
Kuang and colleagues reported that oral administration of 40mg/kg
ligustilide exerted a neuroprotective eﬀect against Aβ neurotoxicity
when administered intracerebroventricularly [93]. In addition, the
compound improved the cognitive deﬁcits and authors suggested that
the eﬀects could be explained by the inhibitory eﬀect of glial cells and
TNF-α-signaling pathway. Recently, in a 7-month-old APP/PS1 mice
assay, Xu and co-authors [94] veriﬁed that 8 weeks of daily intragastric
administration of ligustilide alleviate mitochondrial dysfunction and
morphology issues, exert an antioxidation eﬀect by reducing the levels
of malondialdehyde (MDA) and reactive oxygen species (ROS), reduces
Aβ levels, provided synaptic protection and ameliorates memory def-
icit. Furthermore, it has been reported that the positive eﬀect of li-
gustilide on cognitive process can be inhibited by scopolamine - an
inhibitor of acetylcholinesterase activity - and thus act via enhancing
cholinergic function and memory processes [95].
Interestingly, chronic administration of ligustilide prevented the
development of AD-like neuropathologies and memory impairment in
SAMP8 mice. One potential neuroprotective mechanism proposed is
through Klotho upregulation, which is an aging-suppressor gene that
causes systemic anti-aging and increases longevity. The increase in
brain Klotho levels inhibited the IGF-1 pathway and decreased oxida-
tive stress in the brain [96].
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3.1.5. Bilobalide - Ginkgo biloba extract
The seeds and leaves of Ginkgo biloba (Ginkgoaceae) have been used
in traditional Chinese medicine. Although the extracts of the Ginkgo
biloba leaves contain ﬂavonoids, bilobalide and ginkgolides that can
cross the BBB and also produce pharmacological eﬀects in the CNS, a
recent study published by Vellas and colleagues reported the Ginkgo
biloba extract was ineﬀective in lowering the risk of AD [97]. It has been
reported that the Ginkgo biloba extract presented an antioxidant eﬀect
on mitochondrial oxidative stress and prevented Aβ-induced neuronal
apoptosis in neuronal cell cultures. However, although the total extract
may not be eﬀective in the prevention of AD, it has been reported that
bilobalide, a sesquiterpenoid extracted from Ginkgo biloba leaves, pre-
sented neuroprotective eﬀects against Aβ42 [98]. Furthermore, Shi and
colleagues reported that bilobalide increased sAβPPα secretion in SH-
SY5Y cells, while decreased Aβ production [99]. Moreover, bilobalide
up-regulated the ADAM10 expression through an up-regulation of PI3K
activity without increasing PKC activity [100]. Accordingly, Yin and
coworkers reported that bilobalide prevented Aβ25–35 induced cognitive
loss in Morris water maze test. The authors suggested that bilobalide
beneﬁcial eﬀects are mediated by the inhibition of oxidative stress and
the prevention of neuronal apoptosis in the brain of treated rats [101].
3.1.6. Curcumin
Curcumin is the major constituent of the Asian spice, turmeric,
isolated from the rhizome of Curcuma longa. This natural product, due
to its size, can easily penetrate the BBB, and it was suggested as a
promising AD therapy [102]. In an excellent review, Reddy and col-
leagues described in detail the mechanisms involved in the neuropro-
tective eﬀects of curcumin in AD preclinical models [103]. Among
them, curcumin demonstrated antioxidant, anti-inﬂammatory, autop-
hagic eﬀects in APP/PS1 mice, decreasing Aβ levels and BACE-1 ac-
tivity, among other beneﬁcial eﬀects. Narasingapa and coworkers de-
veloped curcumin amino acid conjugates that showed a potent α-
secretase stimulatory activity [104]. The mechanisms underlying these
eﬀects are still unclear, however, it seems that curcumin can activate
SIRT1 expression [105], transcriptionally increasing ADAM10 levels
[106].
In addition, some clinical trials evaluated the eﬃcacy of this drug in
AD. The clinical trial NCT00164749 investigated the potential eﬀec-
tivity of curcumin and Ginkgo biloba on AD progression, but the results
showed that the combination failed to reduce Aβ levels in the blood of
AD patients or to improve their cognition.
The clinical trial NCT00099710 examined the safety and tolerability
of curcumin and determined its eﬀect on patients with mild to moderate
AD. Ringman and colleagues published the results of this study,
demonstrating no beneﬁcial eﬀects of curcumin in decreasing CSF Aβ
levels. They suggested that problems with bioavailability could be re-
sponsible for the observed ineﬃcacy of this drug [107].
3.1.7. Bryostatin-1
This drug is responsible for the stimulation of α-secretase activity
through activation of PKC and subsequent promotion of sAβPPα se-
cretion [108]. Interestingly, this a typical compound of animal origin
that is able, at nanomolar concentrations, to promote an increase in
PKC activity, increase sAβPPα levels and decrease brain Aβ levels
without inducing pro-tumor activity [109].
It was demonstrated that administration of Bryostatin-1 in the APP/
PS1 model of familial AD improved cognitive deﬁcits compared to
control mice [110]. Some clinical trials evaluated the eﬃcacy of this
drug in AD patients. The clinical trial NCT02221947 is a single center,
randomized, double-blind, placebo-controlled, parallel group’s trial in
AD patients. The patients received a single intravenous dose of placebo
or 25 μg/m2 bryostatin-1 and safety, eﬃcacy, pharmacokinetics, and
pharmacodynamics of drug were investigated. The bryostatin was able
to increase the Mini-Mental State Examination (MMSE) score, was well
tolerated in AD patients and no drug-related adverse events were re-
ported [108].
The clinical trial NCT02431468 evaluated the eﬀects of bryostatin-1
(two doses with 20 and 40 μg administered i.v.) in the treatment of
moderately severe to severe AD. No clinical data from the study has
been currently reported.
3.1.8. [6]-Gingerol
Gingerol (Zingiberaceae family) is a dietary compound that can be
found in a number of plants. Its major phenolic component is the [6]-
gingerol, which has antitumor, antimutagenic, antioxidant, anti-apop-
totic, anti-inﬂammatory, cardio- and hepatoprotective properties [111].
[6]-Gingerol has neuroprotective eﬀects by suppressing the GSK-3β
activation and increasing Akt activity [112]. In addition [6],-gingerol
was able to restore Aβ25-35-depleted endogenous antioxidant glu-
tathione and aﬀected Aβ25-35-induced intracellular ROS accumulation
by upregulating heme oxygenase-1 (HO-1) and γ-glutamylcysteine li-
gase (GCL) in SH-SY5Y cells mediated by NF-E2-related factor 2 (Nrf2).
Therefore [6]-gingerol can be a potential drug for AD prevention and/
or treatment through its antioxidant capacity [113] Fig. 3.
3.2. Other compounds that activate α-secretase pathway
Besides to the natural compounds that can modulate the ADAM10
described earlier (Figs. 2 and 3), it was reported that Myricetin, a
Fig. 3. Chemical structure of natural compounds involved in ADAM10 modulation.
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quercetin isomer, induced α-secretase and decreased Aβ levels reg-
ulating also BACE-1 activity [114]. Genistein is an isoﬂavonoid of the
Leguminosae family that can activate PKC signaling and thus α-secre-
tase activity increasing sAβPPα levels [115]. In addition, it can de-
crease Aβ levels through the BACE-1 inhibition and improve cognition
via inhibiting acetylcholinesterase activity. Interestingly, Avramovich
and co-workers reported that non-steroidal drugs such as nimesulide,
ibuprofen and indomethacin, can increase α-secretase activity, thereby
reducing the Aβ formation and thus, as we have proposed in previous
studies, it is a suitable cofactor strategy for AD prevention [116].
Shuck and co-authors analyzed 313 extracts of medicinal plants
indigenous to Korea for ADAM10 gene in SH-SY5Y cells. The extract of
Caragana sinica (Buc'hoz) Rehder was identiﬁed as the best candidate
for ADAM10 gene enhancers in peripheral tissue, without side eﬀects.
By fractionating Caragana sinica extract, alpha-viniferin was identiﬁed
as one of the biologically active components that can achieve BBB pe-
netrance and might be used as novel therapeutic options for treating AD
by increasing ADAM10 gene expression [117].
Resveratrol (RSV) also is a natural polyphenolic ﬂavonoid, which
can be found in grapes and red wine, and exerts neuroprotective and
antioxidant properties [118]. RSV decreased total cholesterol con-
centration in hypercholesterolemic rats [119]. The direct and positive
eﬀects of RSV on AD pathology are related to the activation of nuclear
retinoic acid receptors, which may activate ADAM10 gene transcription
[65], as discussed earlier in this review. RSV treatment under experi-
mental conditions in Chinese hamster ovary (CHO) cells expressing
human AβPP695 containing a Swedish mutation showed a signiﬁcant
increase in ADAM10 expression, especially its mature form and maybe
the reason for the increase of the AβPP α-CTF fragment after RSV
treatment [120].
Acetyl-L-carnitine (ALC) is a compound that helps to maintain mi-
tochondrial bioenergetics and decreases the oxidative stress associated
with aging [121]. ALC is present at high concentrations in the brain and
contains portions of carnitine and acetyl, both with neurobiological
properties. Carnitine is important in the β-oxidation of fatty acids and
the acetyl portion can be used to maintain acetyl-CoA levels. Other
reported neurobiological eﬀects of ALC include brain energetic mod-
ulation and phospholipid metabolism, synaptic morphology and sy-
naptic transmission via multiple neurotransmitters [122]. ALC is active
in cholinergic neurons, where it is involved in acetylcholine production.
ALC treatment has been shown to stimulate α-secretase activity and,
consequently, to reduce the β-secretase-mediated pathway [123]. It is
known that ALC pre-treatment of cortical neurons in culture sig-
niﬁcantly reduced Aβ-induced cytotoxicity, protein oxidation and lipid
peroxidation in a concentration-dependent manner [121]. In hippo-
campal neurons, treatment with ALC caused an increase in ADAM10
levels in the post-synaptic compartment [124–126]. Another study
showed that ALC can inﬂuence the non-amyloidogenic metabolism of
AβPP, without aﬀecting total AβPP and ADAM10 levels. The data
suggest that ALC did not alter ADAM10 protein levels, but rather in-
ﬂuenced the delivery of ADAM10 to the post-synaptic compartment,
and consequently positively modulated its enzymatic activity towards
AβPP in neuronal cells [123].
4. Future perspective
4.1. Challenges of ADAM10 as a predictor of therapy outcome for
Alzheimer’s disease
ADAM10 expression and/or activity dysregulation are involved in a
number of human pathologies [127], ranging from those aﬀecting the
brain [32,128], liver [129], epithelium [130,131], immune system
[132–134] to cancer [135–137]. In this way, ADAM10 activation or
inhibition therapies will diﬀer according to the pathology (see the re-
view from Wetzel and co-authors) [127]. However, experimental trials
verify better tolerance in its moderate upregulation than in its
inhibition [127]. ADAM10 overexpression in adult mice can cause
changes in the expression of more than 300 genes, however, eﬀects
were mild and age-dependent as in the case of Notch signaling, one of
ADAM10′s main substrates [138]. Another important point to consider
is the great functional similarity of ADAM10 and ADAM17, so that they
could be co-aﬀected and, in some cases, develop undesirable situations,
such as inﬂammation and impaired tissue regeneration [139].
New natural treatments and preventive interventions on ADAM10
regulation for AD patients are necessary, however, they have to be
carefully investigated in animal models and later in clinical trials,
considering the wide variety of ADAM10 substrates, with e.g. more
than 90 just in the brain [140]. In addition, most studies have used in
vitro approaches to identify substrates for ADAM10. Thus, besides the
urgent need to conﬁrm these candidates in vivo, also attention is re-
quired for new substrates that may limit ADAM10 activation, due to
toxic eﬀects. Despite its possible beneﬁt when activated for patients
with AD, it can be highly detrimental in other situations, such as cancer,
tumor progression, metastasis, FXS, inﬂammation and others [53,55].
In this way, for future perspectives, it will be necessary to develop fo-
cused drugs on tissue-substrate-speciﬁc ADAM10 interaction as these
approaches could reduce unwanted systemic eﬀects. Moreover, since
AD is currently seen as a multifactorial disease, multi-drug therapies
should be considered that besides ADAM10 target other molecules or
pathways, for example, neurogenesis.
Taken together, all the information about ADAM10 clearly indicates
that more studies must be performed in order to deﬁnitely demonstrate
its role in the underlying AD mechanisms. A deep investigation of
ADAM10 functions would oﬀer new understandings of its biological
mechanisms of action, as well as provide novel possibilities for the
development of AD treatments or predicting therapeutic outcomes.
Finally, the possibility of measuring ADAM10 alterations in peripheral
cells of AD patients can be exploited to monitor the response of the
patients to therapeutic strategies targeting ADAM10 activity.
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